Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Ligand Pharmaceuticals Inc (NASDAQ:LGND)

99.64
Delayed Data
As of Sep 27
 -13.45 / -11.89%
Today’s Change
79.66
Today|||52-Week Range
139.79
-8.10%
Year-to-Date
Here's Why Ligand Pharmaceuticals Inc Is Plunging Today
Sep 27 / MotleyFool.com - Paid Partner Content
5 Stocks With Amazon-Like Growth Potential
Sep 22 / MotleyFool.com - Paid Partner Content
Kite Pharma Reports Favorable Data from Lymphoma Study
Sep 27 / Zacks.com - Paid Partner Content
Ligand (LGND) Inks Deal with TeneoBio for OmniAb Technology
Sep 19 / Zacks.com - Paid Partner Content
GW Pharma Attains 52-Week High on Positive Epidiolex Data
Sep 27 / Zacks.com - Paid Partner Content
Novartis Reports Positive Phase II Data on Migraine Drug
Sep 16 / Zacks.com - Paid Partner Content
Regeneron, Sanofi Skin Disease Drug Under Priority Review
Sep 26 / Zacks.com - Paid Partner Content
Epizyme Receives Milestone from Glaxo for Lymphoma Drug
Sep 16 / Zacks.com - Paid Partner Content
Endo Appoints New CEO, Keeps Q3 & '16 View, Stock Jumps
Sep 26 / Zacks.com - Paid Partner Content
Roche Ocrevus Positive in Phase III Multiple Sclerosis Trials
Sep 15 / Zacks.com - Paid Partner Content
3 Top Biotech Stocks to Buy on Sale
Sep 26 / MotleyFool.com - Paid Partner Content
Shire's Immunodeficiency Treatment Cuvitru Gets FDA Approval
Sep 15 / Zacks.com - Paid Partner Content
Ligand Inks CNS License Agreement with Seelos Therapeutics
Sep 23 / Zacks.com - Paid Partner Content
Ligand (LGND) Commences Phase II Type II Diabetes Study
Sep 14 / Zacks.com - Paid Partner Content
Teva Reports Positive Phase III Tardive Dyskinesia Data
Sep 23 / Zacks.com - Paid Partner Content